Evaluation of thalidomide in the treatment of canine malignant mammary gland neoplasms

• Grant number: 14/01329-9
• Support Opportunities: Scholarships in Brazil - Doctorate
• Start date: May 01, 2014
• End date: September 30, 2016
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
• Principal Investigator: Geovanni Dantas Cassali
• Grantee: Cecília Bonolo de Campos
• Host Institution: Faculdade de Ciências Agrárias e Veterinárias (FCAV). Universidade Estadual Paulista (UNESP). Campus de Jaboticabal. Jaboticabal , SP, Brazil

Abstract

Mammary tumors are among the most common neoplasms of the female dog and surgery is the treatment of choice. Chemotherapy has been used in malignant mammary gland tumors as adjuvant therapy. Tumoral angiogenesis is the ability of neoplastic cells to induce the formation of new blood vessels and it allows the rational use of antiangiogenic therapies. Thalidomide mainly presents an antiangiogenic and immunomodulatory action and has been proposed for the treatment of veterinary and human neoplasms. This therapy seems to be beneficial in the treatment of bitches diagnosed with malignant mammary gland neoplasms. The aim of this new treatment proposal is disease control, overall survival increase, and maintenance of the quality of life of the patient. Therefore, the aim of this paper is to evaluate the administration of thalidomide in association to chemotherapy with carboplatin and surgical exision in advanced canine mammary cancer. At least 24 bitches will be evaluated, divided according to the different proposed treatments. Histopathological analysis, histological grading, morphometric analysis of the inflammatory infiltrate, and immunohistochemistry for Ki-67 and CD31 will be performed in order to evaluate the primary neoplasms, and tumor microvessel density and the inflammatory infiltrate in primary neoplasms before the thalidomide treatment and in distant metastasis obtained after the thalidomide treatment. Follow-up of all patients will be held for at least one year, in order to obtain overall survival. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DE CAMPOS, CECILIA BONOLO; LAVALLE, GLEIDICE EUNICE; MONTEIRO, LIDIANNE NARDUCCI; ARANTES PEGAS, GABRIELA RAFAELA; FIALHO, SILVIA LIGORIO; BALABRAM, DEBORA; CASSALI, GEOVANNI DANTAS. Adjuvant Thalidomide and Metronomic Chemotherapy for the Treatment of Canine Malignant Mammary Gland Neoplasms. IN VIVO, v. 32, n. 6, p. 1659-1666, NOV-DEC 2018. (14/01329-9)

DE CAMPOS, C. B.; LAVALLE, G. E.; LIGORIO, S. FIALHO; NUNES, F. CAMARGO; CARNEIRO, R. A.; AMORIM, R. L.; CASSALI, G. D.. Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas. VETERINARY RECORD, v. 179, n. 20, p. 514-U63, NOV 2016. (14/01329-9)

Academic Publications

(References retrieved automatically from State of São Paulo Research Institutions)

CAMPOS, Cecília Bonolo de. Evaluation of thalidomide in the treatment of canine malignant mammary gland neoplasms. 2016. Doctoral Thesis - Universidade Estadual Paulista (Unesp). Faculdade de Ciências Agrárias e Veterinárias. Jaboticabal Jaboticabal.